Objective. To determine the risk of newly recorded myocardial infarction (MI) and stroke among incident GCA cases compared with controls from the general population. We also evaluated time trends during follow-up.
Introduction
GCA is the most common vasculitis in adults that affects the large-and medium-sized arteries [1] . Although the disease typically affects superficial temporal arteries [1] , the involvement of other vessels, leading to myocardial infarction (MI) [2, 3] and cerebrovascular accident [4, 5] , has also been described. However, studies looking at the risk of cardiovascular events have been limited and yielded conflicting results [68] .
A retrospective cohort study from Canada [7] found an increased risk of cardiovascular disease (CVD) (coronary artery disease, stroke, peripheral arterial disease, aneurysm or aortic dissection) among GCA patients, with an adjusted hazard ratio (HR) of 2.1 (95% CI 1.5, 3.0), when compared with unaffected controls. Similarly, GonzalesGay reported a 3% increased risk of vertebrobasilar stroke 4 weeks after diagnosis in 287 consecutive patients with GCA [8] . Recently, a UK-based study [6] found that patients with GCA have an increased risk of MI [adjusted HR 2.00 (95% CI 1.67, 2.40)] and stroke [adjusted HR 1.27 (95% CI 1.05, 1.54)]. The authors reported that the risk was highest in the first month after the diagnosis [HRs 11.89 (95% CI 2.40, 59.00) and 3.93 (95% CI 1.76, 8.79) for MI and stroke, respectively]. This was the first study to show evidence that cardiovascular complications occur early as well as late after disease onset. However, some biases may limit the validity and generalizability of these results, including the use of prevalent cohorts from primary care [6] , the use of controls not representative of the general population [8] and the lack of adjustment for unmeasured confounders [6] or competing risks [7] .
To address some of the limitations of the previous studies, we aimed to evaluate whether patients with GCA have an increased risk of MI or stroke when compared with age-, sex-and entry timematched controls randomly selected from the general population. Moreover, we examined the effect of time on trends of such risks over the first 5 years after the GCA diagnosis.
Methods

Data source
Universal, publically funded health coverage is available for all residents in British Columbia (BC), Canada (population 4.7 million). Population Data BC captures general populationbased administrative data, including linkable data files on all provincially funded healthcare professional visits [9] , hospital admissions and discharges [10] , interventions [9] , investigations [9] , demographic data [11] , cancer registry records [12] and vital statistics [13] since 1990. Furthermore, Population Data BC encompasses the comprehensive drug database PharmaNet [14] , which includes all dispensed medications for all BC residents since 1996. Numerous general populationbased studies have been successfully conducted using these databases [1521] .
Study design
We conducted a matched cohort analysis for incident MI, stroke or both, combined among individuals with incident GCA (GCA cohort) as compared with age-, sex-and entry timematched individuals without GCA randomly selected from the general population (comparison cohort) using data from Population Data BC. For the comparison cohort, we matched up to 10 individuals without GCA to each GCA case based on age, sex and calendar year of study entry.
We created an incident GCA cohort with cases diagnosed for the first time between January 1996 and December 2010, that had no GCA diagnosis recorded for at least 6 years previously (i.e. since January 1990) to ensure we captured truly incident GCA cases. Our study definition of GCA specified: patients older than 40 years of age; one International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for GCA by a rheumatologist (ICD-9-CM 446.5), or from hospital (ICD-9-CM 446.5, ICD-10 M31.5), or two ICD-9-CM codes for GCA, at least 2 months apart, and within a 2-year period by a non-rheumatologist physician; and at least one prescription for oral glucocorticoids between 1 month before and 6 months after the index date.
Similar GCA definitions have been used in previous studies using administrative data, and were found to have a positive predictive value of 91% [22, 23] . To further improve specificity, we excluded individuals with at least two visits >2 months apart subsequent to the GCA diagnostic visit with other inflammatory disease diagnoses (e.g. RA, SpA, SLE).
For each comparison cohort we matched up to 10 individuals, randomly selected from the general population, without GCA to each GCA case based on age, sex and calendar year of study entry. We excluded GCA cases and controls with MI or stroke prior to the index date (i.e. the date of diagnosis, or matching date for controls).
Ascertainment of MI or stroke
The primary outcomes were the first MI or stroke event occurring during the follow-up period. We identified MI (ICD-9-CM 410 or ICD-10 I21) and stroke (ICD-9-CM codes: 433 and 434 or ICD-10 codes: I63I66) events from hospitalization data [10] , and defined death from MI and stroke based on the death certificate diagnostic codes [13] , including out-of-hospital deaths. Transient ischaemic attacks were not included. The validity of ICD codes for identifying MI and stroke has been widely demonstrated, including in the Canadian context [2427] .
Assessment of covariates
Covariates consisted of potential risk factors for MI and stroke assessed during the year before the index date. We included healthcare utilization, medication use (glucocorticoids, HRT, contraceptives, cyclooxygenase (COX)-2 inhibitors and NSAIDs), cardiovascular medications (anti-hypertensives, cardiac glycosides, diuretics, antiarrhythmics, nitrates and anticoagulants), fibrates and statins [14] . Aspirin use was not included in our assessment because it is available over the counter. Additionally, a modified Charlson co-morbidity index for administrative data was calculated in the year before the index date [28, 29] .
Cohort follow-up
Our study cohorts spanned the period 1 January 1996 to 31 December 2010. Individuals with GCA entered the case cohort after all inclusion and exclusion criteria had been met; controls entered the comparison cohort after a matched doctor's visit in the same calendar year. Participants were followed until they either experienced an outcome, died, dis-enrolled from the health plan (left BC, 1%) or the follow-up period ended (31 December 2010), whichever occurred first.
Statistical analysis
We compared baseline characteristics of the GCA and comparison cohorts. We identified incident cases of MI and stroke during the follow-up period and calculated incidence rates (IRs) of MI and stroke, both individually and in combination (i.e. CVD), per 1000 person-years. We used Cox proportional hazard regression models to assess the risk of MI and stroke associated with GCA after adjusting for covariates. We entered confounders one at a time into the Cox models in a forward selection according to each confounder's impact on the hazard ratio of GCA, relative to the HR in the model selected in the previous step. The cut-off for the minimum important relative effect at each step was set at 5%. In order to evaluate the impact of duration of GCA (i.e. follow-up time after GCA diagnosis), we estimated the HR yearly for the first 5 years.
Sensitivity analysis
We performed three sensitivity analyses to test the robustness of our results. First, we estimated the cumulative incidence of each event accounting for the competing risk of death according to Lau et al. [30] and expressed the results as sub-distribution HRs with 95% CIs. Second, we repeated the analysis using a stricter definition of GCA exposure that was limited to subjects with GCA and five or more outpatient prescriptions for glucocorticoids on or after the diagnosis of GCA. Third, to quantify the potential impact of unmeasured confounders, we performed another sensitivity analysis assessing how a hypothetical unmeasured confounder (e.g. smoking) might have affected our estimates of the association between GCA and the risk of MI or stroke [31] . We simulated unmeasured confounders with their prevalence ranging from 10% to 20% in the GCA and control cohorts, and odds ratios (ORs) for the associations between the unmeasured confounder and CVD, MI and stroke ranging from 1.3 to 3.0.
We used SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA) for all analyses. For all HRs, we calculated 95% CIs. All P-values were two sided. No personal identifying information was made available as part of this study. Procedures used were in compliance with British Columbia's Freedom of Information and Privacy Protection Act. Ethics approval for this study was obtained from the University of British Columbia.
Role of the funding source
The design, conduct and reporting of the study was not impacted by the funding sources.
Results
Our primary analysis included 809 incident GCA cases without MI or stroke, and 8577 age-, sex-and entry timematched individuals in the control cohort. The total follow-up time for the GCA and comparison cohorts was 2038 person-years and 30 295 person-years, respectively. Table 1 summarizes the baseline characteristics of both the GCA and control cohorts. Overall, patients with GCA used cardiovascular drugs, glucocorticoids, diabetes medications, NSAIDs and COX-2 inhibitors more than individuals in the comparison cohort. Lower Charlson comorbidity index scores and higher health care resource utilization were also documented for patients in the GCA cohort during the last 12 months prior to the diagnosis of GCA.
GCA was associated with a substantially increased risk for MI and stroke events ( Table 2 and Fig. 1 Table 2 ).
The time-based risk after diagnosis of GCA revealed that the risk was substantially higher in the first year after the diagnosis of GCA for both MI and stroke, with HRs of 4.76 (95% CI 3.29, 6.88) and 3.20 (95% CI 2.11,
FIG. 1 Cumulative incidence of cardiovascular disease in GCA
Cumulative incidence for myocardial infarction (A), stroke (B) and overall cardiovascular disease (C) in the cases with incident GCA compared with non-GCA subjects. Fully adjusted models entered confounders one at a time into the Cox models in a forward purposeful selection algorithm according to each confounder's impact on the HR in the previous step (minimum cutoff was set at 5%). Glucocorticoids and number of physician visits made into the final selected models for all outcomes, but no NSAIDs including Cox-2 inhibitors. MI: myocardial infarction; HR: hazard ratio.
4.87), respectively; the risk decreased in subsequent years, but remained statistically significant for over 5 years following the initial diagnosis (Table 3) .
Sensitivity analysis
HRs from the analysis of the association between GCA and study outcomes that accounted for the competing event of death gave slightly attenuated estimates, but remained significant (Table 4) . In addition, when we restricted our analysis to cases that received five or more prescriptions for glucocorticoids and the matched controls, our point estimates remained statistically significant (Table 4) .
Discussion
This large population-based study showed a significantly increased risk of incident MI and stroke in patients with GCA at the general population level. It also demonstrated that the risk for both outcomes is highest within the first year of diagnosis, although it remains significant even after 5 years of follow-up. The literature exploring the risk of CVD in GCA patients is scarce. In 2005, Ray and colleagues [7] compared the risk of CVD in patients with GCA with those with OA and with a control group from the general population. Their primary composite outcome was incident coronary artery disease, stroke, peripheral arterial disease or aneurysm. They reported an adjusted HR of 1.6 (95% CI 1.1, 2.2) in patients with GCA, compared with unaffected controls. However, in that study the authors only used ICD coding for identification of patients with new GCA, whereas in the current study we have used a more stringent definition for GCA that includes the use of glucocorticoids. Our definition has been previously validated, with a positive predictive value of 91% [22, 23] .
Our results are in agreement with a recent study by Tomasson and colleagues [6] , who used The Health Improvement Network (THIN), an electronic medical record database that has information from primary care physicians in the UK willing to participate in data collection for a subsample of their practices. The authors reported a HR of 1.70 (95% CI 1.51, 1.91) for the combined outcome of MI, stroke or peripheral vascular disease in patients with GCA. The individual HRs for MI, stroke and peripheral arterial disease were 2.06 (95% CI 1.72, 2.46), 1.28 (95% CI 1.06, 1.54) and 2.13 (95% CI 1.61, 2.81), respectively. The authors also found that the risk was highest in the first month after diagnosis of GCA, and decreased in the subsequent 6 months.
The current study used a case definition that employed GCA diagnostic codes from outpatient visits [9] , Hypothetical prevalence of the unmeasured confounder in the GCA cases.
b Hypothetical level of association between the unmeasured confounder and the outcome. Primary analysis is the fully adjusted model. Sensitivity analysis 1 (subdistribution Cox model); accounting for the same covariates as the primary analysis in addition to age and sex. Sensitivity analysis 2 (5+ glucocorticoid prescriptions) and Simulated confounder models included additional covariates per the selection algorithm. HR: hazard ratio; OR: odds ratio; MI: myocardial infarction. Cardiovascular disease in GCA rheumatologists [9] or hospitalizations [10] , while the study that used THIN data relied on cases identified in the records from primary care physicians. Thus, our study was more likely to capture all MI and stroke events because we utilized hospitalization data [10] and death certificate codes [13] , whereas the THIN database relied only on general practitioners to record such events, thus increasing the probability that events may not have been recorded. Another reason for the higher risk of MI, stroke or a combination of both that was found in our study is that we likely captured a more representative spectrum of mild and severe GCA cases. We included cases recorded by both rheumatologists and non-rheumatologist physicians, whereas other studies, such as the one utilizing the THIN database, may have missed severe cases that would have only been captured by specialists, which may or may not have been at higher risk of CVD. In summary, the study conducted using THIN is not a truly general populationbased study, and thus has limited generalizability.
Moreover, in our study we used a stricter methodology, which included adjusting for competing risks, unmeasured confounders and an extensive list of covariates, including all dispensed medications [14] , and health care resource use [9, 10] . Despite this, our results remained statistically significant, suggesting that the increased risk is mainly due to GCA. Furthermore, the presence of the highest risk of MI and stroke in the first year after diagnosis suggests that inflammation may play a key role in the pathogenesis of cardiovascular outcomes in GCA.
Our results are reflective of a growing body of evidence that patients with chronic inflammatory conditions are at increased risk of cardiovascular events, including venous thromboembolism [21] . This has been demonstrated for other rheumatological conditions such as SLE [32] , RA [33] and DM [20] . Furthermore, there is mounting evidence that patients with vasculitis may also be at increased risk [21, 34, 35] .
A recent paper [36] suggested that vasculitides are associated with accelerated atherosclerosis independent of traditional risk factors. Patients with vasculitis can have low levels of high-density lipoproteins, which may be proinflammatory in nature [37] , and have limited antioxidant activity [38] . Furthermore, downregulation of protective Treg [39] , increased concentration of modified low-density lipoproteins (LDLs), resulting in the formation of foam cells; the release of pro-inflammatory cytokines [40] can further contribute to the promotion of atherosclerosis in systemic vasculitis. Currently, administration of highdose glucocorticoids is the standard of care in patients with GCA [41] . This treatment carries its own morbidities, including hypertension, diabetes mellitus and dyslipidaemia, which further contribute to cardiovascular risk factors [42, 43] . Nevertheless, we adjusted for these differences at baseline. Yet, a study done by Kremers et al. [44] did not find an increased risk of CVD in patients with PMR who were treated with glucocorticoids [44] . However, similar studies have not been done in patients with GCA.
As previously mentioned, our study had the advantage of the utilization of nearly the entire population of BC, making our results generalizable to the population at large. In addition, we were able to adjust for pre-existing comorbidities, health resource utilization and medication use for all cases and controls, competing risk of death, and unmeasured confounders. We also used one of the strictest case definitions for administrative databases available for GCA.
Potential limitations of our study include those inherent to all observational studies utilizing administrative data. Both the diagnosis of GCA and the outcomes of MI and stroke were based on ICD codes. However, a number of studies have also investigated the accuracy of ICD-9 and ICD-10 coding for both MI [45, 46] and stroke [25, 47] , and both have been found to be valid and accurate. Moreover, due to the nature of our data, we did not have access to temporal artery biopsy results, which are considered the gold standard [48] for GCA diagnosis, leading to possible false positive results. However, we used one of the strictest definitions of GCA for administrative data in the literature, and our definition has been previously validated with a positive predictive value above 90%. Furthermore, when we restricted the definition of GCA to patients who received more than five prescriptions of glucocorticoids, our results remained statistically significant. We also adjusted for all risk factors of CVD available in our database.
We did not have access to smoking status as a potential cofounder. Furthermore, we did not adjust for aspirin use, given it is available over the counter. Again, when we adjusted for the potential impact of unmeasured cofounders in the sensitivity analyses, our findings persisted, suggesting that our results are robust. Lastly, we did not have access to disease-specific presentations such as headache, fever or presence of jaw claudication, and cannot establish a correlation between these findings and cardiovascular outcomes as cited in the paper.
In summary, we found that patients with GCA have a 3-fold increased risk of MI and a 2-fold increased risk of stroke compared with the general population. The risk was greatest in the first year after the diagnosis, suggesting the potential pathogenic role of inflammation in the development of these outcomes. Our findings are clinically important because they will alert physicians to monitor patients closely and to traditional risk factors for CVD to minimize this risk in patients with GCA.
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